Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In cases of locally advanced, potentially curable pancreatic cancer, a combination of drugs enhances the results of radiation therapy.

2.

Study identifies new target for obesity-related breast cancer

3.

Limits to Anti-Nausea Pill Coverage Wear on Cancer Patients and Doctors

4.

Capivasertib Wins Metastatic Prostate Cancer Approval

5.

New research uncovers link between cancer pathway and blood-retina barrier function


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot